Table of Contents Table of Contents
Previous Page  9 / 40 Next Page
Information
Show Menu
Previous Page 9 / 40 Next Page
Page Background

Oral Anticoagulants

7

nmdental.org

O

ver the past several years, the FDA has approved some

new oral anticoagulant medications that provide an

alternative regimen for traditional Warfarin patients.

This article will review those medications and how I manage

surgery in an office setting.

Pradaxa (dabigatran etexilate)

was approved

by the FDA in 2010. It is a direct thrombin inhibitor indi-

cated to reduce the risk of stroke and systemic embolism in

patients with non-valvular a trial fibrillation; and for the treat-

ment and reduction of risk of deep vein thrombosis and pul-

monary embolism. Pradaxa is taken twice daily and does not

require INR monitoring (a major convenience for patients).

Dental Management:

Pradaxa has a half life of 13 hrs

and is around 90% eliminated in 24 hrs in patients with nor-

mal renal function. Minor surgical procedures can usually be

performed after this amount of time has passed. In patients

with impaired renal function, two or more days of holiday is

recommended. As with any modification of medication for

surgery, please consult and coordinate with the patients treat-

ing physician prior to any planned surgical procedure.

Xatelto (rivatoxaban)

was approved buy the FDA

in 2011. It is a factor Xa inhibitor indicated for the prophy-

laxis of deep vein thrombosis (DVT) in patients undergoing

knee or hip replacement surgery, to reduce the risk of stroke

in people who have abnormal heart rhythm (non-valvular atri-

al fibrillation) and to treat and reduce the risk of deep vein

thrombosis (DVT) or pulmonary embolism (PE). Xarelto is

taken once daily and does not require INR monitoring.

Dental Management:

Xarelto has a half life of 5–9 hrs

in patients with normal renal function. Similar to Pradaxa,

discontinuation is recommended at least 24 hrs prior to mi-

nor surgical procedures.

Eliquis (apixaban)

was approved by the FDA in

2012. It is a factor Xa inhibitor anticoagulant indicated to

reduce the risk of stroke and systemic embolism in patients

with nonvalvular atrial fibrillation, and for the prophylaxis of

deep vein thrombosis (DVT) in patients who have undergone

hip or knee replacement surgery. Eliquis is taken twice daily

and does not require INA monitoring.

Dental Management:

Eliquis has a half life of approxi-

mately 12 hrs. As with the other two medications above, dis-

continuation at least 24 hrs prior to minor surgical procedures

in patients with normal renal function should be adequate.

In my practice, I perform many extensive dent-alveolar proce-

dures. One of my concerns when discontinuing anticoagula-

tion is the increased risk of a thrombotic event in the office or

peri-operative period. I would prefer high risk patients to have

some degree of anticoagulation when they are treated in my

office. Many times, excessive bleeding can be controlled with

local measures (i.e. gel-foam, surgical). I have had good suc-

cess with high risk patients in switching their anticoagulant

therapy to a daily baby aspirin (81 mg) one week prior to their

scheduled surgery. This provides a manageable level of anti-

coagulation for larger procedures. Of course, this is discussed

with their treating physician prior to surgery.

By Eric Tuggle, DDS—Sandia Oral Surgery

Update on New Oral

Anticoagulants (NOAC's)

and Management in the

Surgical Dental Practice